Coya Therapeutics, Inc.
Moat Score — Coya Therapeutics, Inc.
Total Moat Score
4 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Proprietary Treg-focused biologic candidates plus Carnegie Mellon University-licensed exosome-targeting technology provide meaningful, though early-stage, intellectual property. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a small clinical-stage biotech, Coya has no manufacturing or operating cost advantage versus larger, better-funded competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no approved products, Coya has no current pricing power; any future pricing power depends entirely on unproven clinical and regulatory success. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | No network effects apply to a clinical-stage biopharmaceutical pipeline business. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | No commercial product exists yet, so there are no customer switching costs to speak of. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The Treg-focused therapeutic niche has relatively few direct exosome-based competitors, offering a small measure of first-mover positioning if the mechanism proves out. |